Home Tonometry With the I-care Tonometer for Glaucoma

Glaucoma Clinical Trial

Official title:

Home Tonometry for Monitoring Glaucoma:a Pilot Study of the Icare Home Tonometer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02656836
• Other study ID #: REC 15/EM/0217
• Status: Completed
• Start date: November 2015
• Est. completion date: April 2016

Study information

• Verified date: January 2020
• Source: Queen's University, Belfast
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The overall objective of the study is to scope the self-management for self-monitoring glaucoma using home tonometry.

Description:

Monitoring of glaucoma requires frequent evaluation of IOP and disease severity, typically with visual field tests. When a patient is diagnosed with glaucoma an optimum level of IOP (or target IOP) is determined based on patient's characteristics, such as severity of disease and life expectancy. In current models of care patients have their IOP measured at the clinic at different intervals. If the IOP is noted to be high, or above the patient's target, additional treatment is recommended. Accurate and frequent IOP measurements at different points in time are thus imperative.

Tonometry is usually conducted by clinicians in an eye clinic. Some tonometers (e.g., Icare) have the potential to be used by the individual for home monitoring of IOP for patients with suspected glaucoma/glaucoma. Self-monitoring of IOP via home tonometry will allow patients to undergo IOP measurements at different points in time (e.g., early morning and night-time, and it can help determine diurnal changes and spikes).

The overall objective of the current study is to conduct a feasibility pilot study on the home tonometer (Icare), acquiring initial experience with the Icare tonometer. For this purpose investigators will train up to 20 individuals on how to use the device. Investigators will ask them to record in a diary their IOP twice a day for a period of 2 weeks. Investigators will then compare IOP outcomes with the measurement taken at the clinic. Patients and clinicians will be masked to the IOP data.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: April 2016
• Est. primary completion date: April 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Attending the glaucoma clinic for monitoring (for glaucoma or ocular hypertension)

2. Aged 18 years or over

3. Patient deemed able to monitor their IOP at home (by themselves or a helper)

Exclusion Criteria:

1. Not receiving IOP monitoring (for glaucoma or ocular hypertension)

2. Aged <18 years

3. Patients deemed unable to monitor their IOP at home (and do not have someone who can help them) e.g., apparent physical or cognitive impairments that will not allow for the use of a home tonometer

4. Had surgery for their glaucoma (glaucoma surgery only; other surgeries included e.g., cataract surgery)

5. Patient has preexisting corneal disease

Related Conditions & MeSH terms

• Glaucoma

Intervention

Other:
• Home tonometry, diagnostic study
Evaluating intraocular pressure

Locations

Country	Name	City	State
United Kingdom	Centre for Experimental Medicine QUB	Belfast	Co.Antrim

Sponsors (2)

Lead Sponsor	Collaborator
Queen's University, Belfast	Belfast Health and Social Care Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Intraocular Pressure	Intraocular pressure in mmHg units, obtained by tonometers. The investigators will determine agreement of intraocular pressure (IOP) measured using the home tonometer (patient) compared with IOP measured in the clinic.	Two weeks
Secondary	Proportion of Patients Able and Willing to Use the Tonometer	Proportion of patients willing to use the tonometer but are unable to. Patient feedback reported via questionnaire	Two weeks
Secondary	Proportion of Patients With an Adverse Event	Any adverse event or complication associated with the use of the device. Expected side effects will be corneal erosion, and ocular irritation.	One month